BioFactura Granted Chinese Patent For Its StableFastTM Biomanufacturing Platform
BioFactura, Inc. was granted patent rights by China’s State Intellectual Property Office (SIPO) protecting the core technologies of its proprietary StableFastTM Biomanufacturing Platform. SIPO allowed 17 claims broadly covering composition of matter and methods. StableFastTM is BioFactura’s proprietary NS0-based system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on biologics and are single-use technology compatible. The Company is developing high-value biosimilars both internally and collaboratively.
“This new allowance continues BioFactura’s 100% success record with multiple patent grants in the US and internationally for StableFast and significantly expands our market exclusivity for NS0-produced biosimilars in China,” said Darryl Sampey, BioFactura’s President and CEO.
Dr. Jeffrey Hausfeld, Chairman and Chief Medical Officer, stated, “The granting of the Chinese patent for BioFactura’s StableFast Biomanufacturing Platform further enhances our ability to bring our products to a global market. We are excited about the possibility of providing high-quality, cost-effective biosimilar drugs to patients in China and throughout Asia.”
